Menu Close

Sheets Smith Wealth Management Has $2.41 Million Stake in Johnson & Johnson (NYSE:JNJ)

view original post

Sheets Smith Wealth Management trimmed its stake in shares of Johnson & Johnson (NYSE:JNJGet Rating) by 1.1% during the first quarter, HoldingsChannel reports. The fund owned 13,595 shares of the company’s stock after selling 154 shares during the period. Sheets Smith Wealth Management’s holdings in Johnson & Johnson were worth $2,409,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also made changes to their positions in the stock. Gilbert & Cook Inc. raised its holdings in shares of Johnson & Johnson by 5.6% during the first quarter. Gilbert & Cook Inc. now owns 7,086 shares of the company’s stock worth $1,256,000 after acquiring an additional 376 shares during the period. LVW Advisors LLC increased its stake in Johnson & Johnson by 0.3% in the 1st quarter. LVW Advisors LLC now owns 32,331 shares of the company’s stock valued at $5,730,000 after buying an additional 92 shares during the last quarter. SPC Financial Inc. increased its stake in Johnson & Johnson by 4.7% in the 1st quarter. SPC Financial Inc. now owns 16,100 shares of the company’s stock valued at $2,853,000 after buying an additional 723 shares during the last quarter. Mendel Capital Management LLC increased its stake in Johnson & Johnson by 3.9% in the 1st quarter. Mendel Capital Management LLC now owns 7,973 shares of the company’s stock valued at $1,413,000 after buying an additional 296 shares during the last quarter. Finally, D Orazio & Associates Inc. increased its stake in shares of Johnson & Johnson by 16.6% during the 1st quarter. D Orazio & Associates Inc. now owns 7,673 shares of the company’s stock worth $1,360,000 after purchasing an additional 1,095 shares during the last quarter. 68.78% of the stock is currently owned by institutional investors and hedge funds.

Johnson & Johnson Stock Performance

Shares of Johnson & Johnson stock opened at $174.52 on Friday. The company has a 50 day moving average of $175.95 and a 200-day moving average of $174.39. Johnson & Johnson has a 1-year low of $155.72 and a 1-year high of $186.69. The company has a current ratio of 1.39, a quick ratio of 1.14 and a debt-to-equity ratio of 0.39. The company has a market cap of $459.23 billion, a PE ratio of 25.40, a price-to-earnings-growth ratio of 3.28 and a beta of 0.63.

Johnson & Johnson (NYSE:JNJGet Rating) last issued its quarterly earnings results on Tuesday, July 19th. The company reported $2.59 earnings per share for the quarter, topping analysts’ consensus estimates of $2.57 by $0.02. Johnson & Johnson had a net margin of 19.21% and a return on equity of 36.56%. The company had revenue of $24.02 billion during the quarter, compared to the consensus estimate of $23.85 billion. During the same quarter in the prior year, the firm posted $2.48 EPS. The firm’s quarterly revenue was up 3.0% on a year-over-year basis. As a group, equities research analysts forecast that Johnson & Johnson will post 10.05 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 6th. Stockholders of record on Tuesday, August 23rd will be issued a dividend of $1.13 per share. This represents a $4.52 dividend on an annualized basis and a dividend yield of 2.59%. The ex-dividend date of this dividend is Monday, August 22nd. Johnson & Johnson’s dividend payout ratio (DPR) is presently 65.79%.

Insider Buying and Selling

In related news, EVP Kathryn E. Wengel sold 40,000 shares of the company’s stock in a transaction that occurred on Friday, June 10th. The shares were sold at an average price of $173.00, for a total transaction of $6,920,000.00. Following the completion of the transaction, the executive vice president now directly owns 71,311 shares in the company, valued at approximately $12,336,803. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. In related news, CAO Robert J. Decker sold 8,462 shares of the company’s stock in a transaction that occurred on Thursday, May 26th. The shares were sold at an average price of $180.00, for a total transaction of $1,523,160.00. Following the completion of the transaction, the chief accounting officer now directly owns 15,473 shares in the company, valued at approximately $2,785,140. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Kathryn E. Wengel sold 40,000 shares of the company’s stock in a transaction that occurred on Friday, June 10th. The stock was sold at an average price of $173.00, for a total transaction of $6,920,000.00. Following the transaction, the executive vice president now owns 71,311 shares of the company’s stock, valued at $12,336,803. The disclosure for this sale can be found here. 0.35% of the stock is owned by corporate insiders.

Analyst Ratings Changes

JNJ has been the topic of several recent analyst reports. Wells Fargo & Company boosted their price objective on shares of Johnson & Johnson from $190.00 to $195.00 and gave the stock an “overweight” rating in a research note on Wednesday, July 13th. Credit Suisse Group lifted their target price on shares of Johnson & Johnson from $200.00 to $205.00 and gave the stock an “outperform” rating in a report on Wednesday, April 20th. Daiwa Capital Markets began coverage on shares of Johnson & Johnson in a report on Wednesday, June 22nd. They set an “outperform” rating for the company. Morgan Stanley lifted their target price on shares of Johnson & Johnson from $173.00 to $174.00 and gave the stock an “equal weight” rating in a report on Friday, July 8th. Finally, Citigroup cut their price objective on shares of Johnson & Johnson from $205.00 to $201.00 in a report on Wednesday, July 20th. Four research analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $189.89.

Johnson & Johnson Profile

(Get Rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company’s Consumer Health segment offers baby care products under the JOHNSON’S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

Recommended Stories

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJGet Rating).

Receive News & Ratings for Johnson & Johnson Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Johnson & Johnson and related companies with MarketBeat.com’s FREE daily email newsletter.